Given that EZH2 inhibition appears to regulate both MHCI and class II in squamous cell carcinoma cells, this may help to delay or prevent acquired resistance that occurs more readily when only one molecular pathway is altered. Here, EZH2 is linked to squamous cell carcinoma.